180 related articles for article (PubMed ID: 23132335)
41. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
42. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
43. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
[TBL] [Abstract][Full Text] [Related]
44. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.
Lewandowski RJ; Mulcahy MF; Kulik LM; Riaz A; Ryu RK; Baker TB; Ibrahim SM; Abecassis MI; Miller FH; Sato KT; Senthilnathan S; Resnick SA; Wang E; Gupta R; Chen R; Newman SB; Chrisman HB; Nemcek AA; Vogelzang RL; Omary RA; Benson AB; Salem R
Radiology; 2010 Jun; 255(3):955-65. PubMed ID: 20501733
[TBL] [Abstract][Full Text] [Related]
45. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization.
Liu MT; Li SH; Chu TC; Hsieh CY; Wang AY; Chang TH; Pi CP; Huang CC; Lin JP
Jpn J Clin Oncol; 2004 Sep; 34(9):532-9. PubMed ID: 15466827
[TBL] [Abstract][Full Text] [Related]
46. Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma.
Liu CH; Peng CM; Hwang JI; Liang PC; Chen PJ; Abi-Jaoudeh N; Giiang LH; Tyan YS
J Vasc Interv Radiol; 2022 Aug; 33(8):926-933.e1. PubMed ID: 35504436
[TBL] [Abstract][Full Text] [Related]
47. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).
Iezzi R; Cesario V; Siciliani L; Campanale M; De Gaetano AM; Siciliano M; Agnes S; Giuliante F; Grieco A; Pompili M; Rapaccini GL; Gasbarrini A; Bonomo L;
Radiol Med; 2013 Jun; 118(4):555-69. PubMed ID: 23358819
[TBL] [Abstract][Full Text] [Related]
48. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of
Li S; He X; Dang L; Xu F; Fang J; Li F; Wang W
Dig Dis Sci; 2018 Feb; 63(2):321-328. PubMed ID: 29305738
[TBL] [Abstract][Full Text] [Related]
50. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
Chen LC; Chiou WY; Lin HY; Lee MS; Lo YC; Huang LW; Chang CM; Hung TH; Lin CW; Tseng KC; Liu DW; Hsu FC; Hung SK
BMC Cancer; 2019 Mar; 19(1):275. PubMed ID: 30922261
[TBL] [Abstract][Full Text] [Related]
51. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.
Kim YJ; Jung J; Joo JH; Kim SY; Kim JH; Lim YS; Lee HC; Kim JH; Yoon SM
Radiother Oncol; 2019 Dec; 141():95-100. PubMed ID: 31506181
[TBL] [Abstract][Full Text] [Related]
52. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
53. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
55. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
57. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
Prajapati HJ; Kim HS
PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
[TBL] [Abstract][Full Text] [Related]
58. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
[TBL] [Abstract][Full Text] [Related]
59. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
[TBL] [Abstract][Full Text] [Related]
60. Hepatic artery injection of ¹³¹I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study.
Wu L; Yang YF; Ge NJ; Shen SQ; Liang J; Wang Y; Zhou WP; Shen F; Wu MC
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1306-15. PubMed ID: 22588627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
